Format

Send to

Choose Destination
Urol Clin North Am. 2011 May;38(2):119-24. doi: 10.1016/j.ucl.2011.02.002. Epub 2011 Apr 13.

Testosterone and prostate cancer: what are the risks for middle-aged men?

Author information

1
Men's Health Boston, One Brookline Place, Suite 624, Brookline, MA 02445, USA. amorgent@bidmc.harvard.edu

Abstract

With increased recognition of the benefits of testosterone (T) therapy for middle-aged men, there has been a concomitant reexamination of the historical fear that raising T will result in more prostate cancer (PCa). Studies have failed to show increased risk of PCa in men with higher serum T, and supraphysiologic T fails to increase prostate volume or prostate-specific antigen in healthy men. This apparent paradox is explained by the Saturation Model, which posits a finite capacity of androgen to stimulate PCa growth. Modern studies indicate no increased risk of PCa among men with serum T in the therapeutic range.

PMID:
21621078
DOI:
10.1016/j.ucl.2011.02.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center